39th EDRN Steering Committee Agenda --Wednesday, November 9, 2022

39th EDRN Steering Committee Meeting

Wednesday, November 9, 2022

8:00 a.m. - 1:30 p.m. Pacific

South Room

Agenda

 

 

All times are Pacific 

*presenting remotely

7:00 a.m. - 8:00 a.m. Continental Breakfast & Sign-In
8:00 a.m. – 10:30 a.m. Presentations by GI Biomarker Characterization Centers (BCCs) and Clinical Validation Centers (CVCs)
8:00 a.m. – 8:20 a.m. (BCC) Biomarkers for optimizing risk prediction and early detection of cancers of the colon and esophagus, BCC, Fred Hutch
o   William Grady, MD, Fred Hutchinson Cancer Center
o   Cecilia Yeung, MD, Fred Hutchinson Cancer Center
8:20 a.m. – 8:40 a.m. (CVC) The Great Lakes New England Clinical Validation Center:  Past, Present and Future
o   Robert Bresalier, MD, The University of Texas MD Anderson Cancer Center
o   Sapna Syngal, MD, Dana-Farber Cancer Institute
8:40 a.m. – 9:00 a.m. (CVC) Blood-Based Testing for Advanced Adenoma, CVC, UPMC
o   Robert E. Schoen, MD, University of Pittsburgh
o   Cristian Tomasetti, MD, City of Hope
9:00 a.m. – 9:20 a.m. (CVC) Validation of Biomarkers for predicting Barrett's esophagus that will or will not: i) progress towards cancer, or ii) recur after ablation, CVC, Case Western
o   Sanford Markowitz, MD, Case Western Reserve University
o   Joseph Willis, MD, Case Western Reserve University
o   *Amitabh Chak, MD, UH Cleveland Medical Center
o   *Sachin Wani, MD, University of Colorado Anschutz Medical Campus
9:20 a.m. – 9:40 a.m. (CVC) Clinical Validation Center for Hepatocellular Carcinoma, UTSW
o   *Amit Singal, MD, The University of Texas Southwestern
o   Fasiha Kanwal, MD, Baylor College of Medicine
o   Jorge Marrero, MD, University of Pennsylvania
o   Neehar Parikh, MD, University of Michigan
9:40 a.m. – 10:00 a.m. (CVC) The Gulf Coast Great Lakes EDRN Clinical Validation Center in Pancreatic Cancer (GCGLEC)
o   Anirban Maitra, MD, The University of Texas MD Anderson
o   *Eugene Koay, MD., PhD., The University of Texas MD Anderson
10:00 a.m. – 10:30 a.m. Discussion: Identifying Opportunities for Collaboration
10:30 a.m. – 10:50 a.m. Break
10:50 a.m. – 12:00 p.m. Presentations by Early-Stage Investigators: 14 x 5 min presentations (one investigator per center)
10:50 a.m. - 10:55 a.m. #1 Seq-ing the SINEs of Cancer: New Technologies for Early Detection
ESI:
Contact PI: 		*Chris Douville, PhD, Johns Hopkins University
Sanford Markowitz, MD, PhD,  Case Western Reserve University (CVC)
10:55 a.m. - 11:00 a.m. #2 Leveraging artificial intelligence for optimization of active surveillance in prostate cancer.
ESI:
Contact PI: 		*Udit Singhal, PhD, University of Michigan
Arul Chinnaiyan, MD, PhD, University of Michigan (BCC)
11:00 a.m. - 11:05 a.m. #3 Mass Spectrometry-Based Proteomic Biomarker Discovery and Validation Using PRISM-SRM
ESI:
Contact PI: 		Yuqian Gao, PhD, Pacific Northwest National Laboratory
Pacific Northwest National Laboratory (BRL)
11:05 a.m. - 11:10 a.m. #4 Understanding mechanisms underlying sex and gender disparities in liver cancer
ESI:
Contact PI: 		*Nicole Rich, PhD, The University of Texas Southwestern
Amit Singal, MD, UT Southwestern Medical Center (CVC)
11:10 a.m. - 11:15 a.m. #5 ESI at UCLA
ESI:
Contact PI: 		Ashley Prosper, PhD, University of California, Los Angeles
Marc Lenburg, PhD, Boston University (BCC)
11:15 a.m. - 11:20 a.m. #6 Contribution of the microbiome to a metabolomic signature predictive of risk for pancreatic cancer
ESI:
Contact PI: 		*Johannes Fahrmann, PhD, The University of Texas MD Anderson
Anirban Maitra, MD The University of Texas M D Anderson Cancer Center (CVC)
11:20 a.m. - 11:25 a.m. #7 Mass spectrometry-based glycoproteomics for proteogenomic characterization of tumors
ESI:
Contact PI: 		Yingwei Hu, PhD, Johns Hopkins University
Zhen Zhang, PhD, Johns Hopkins University (BCC)
11:25 a.m. - 11:30 a.m. #8 Novel Protein Array and Biomarker Discovery
ESI:
Contact PI: 		*Lusheng Song, PhD, Arizona State University
Joshua LaBaer, MD, PhD, Arizona State University (BCC)
11:30 a.m. - 11:35 a.m. #9 Will our biomarkers have an impact? Estimating the utility of added biomarkers to diagnostic models using intervention probability curves
ESI:
Contact PI: 		Michael Kammer, PhD, Vanderbilt University Medical Center
Eric Grogan, MD, MPH, Vanderbilt -Ingram Cancer Center (CVC)
11:35 a.m. - 11:40 a.m. #10 Multiplex digital methylation-specific PCR for noninvasive screening of lung cancer
ESI:
Contact PI: 		Thomas Pisanic, PhD, Johns Hopkins University
James Herman, MD, University of Pittsburgh School of Medicine (BCC)
11:40 a.m. - 11:45 a.m. #11 Prevalence of Screen Detected Colorectal Neoplasia
ESI:
Contact PI: 		Asama Shaukat, MD, PhD, New York University
Robert Bresalier, MD, The University of Texas MD Anderson Cancer Center (CVC)
11:45 a.m. - 11:50 a.m. #12 Detecting Advanced Adenomas Via Fragmentomics
ESI:
Contact PI: 		Kamel Lahouel, PhD, Translational Genomics Research Institute
Robert Schoen, MD, MPH, University of Pittsburgh Cancer Institute (CVC)
11:50 a.m. - 11:55 a.m. #13 Mortality benefit of a four marker panel for lung cancer screening
ESI:
Contact PI: 		Ehsan Irajizad, PhD, The University of Texas MD Anderson
Samir Hanash, MD, PhD, The University of Texas MD Anderson Cancer Center (CVC)
11:55 a.m. - 12:00 p.m. #14 A four-marker panel for indeterminate pulmonary nodules
ESI:
Contact PI: 		Edwin Ostrin, MD, PhD, The University of Texas MD Anderson
Samir Hanash, MD, PhD, The University of Texas MD Anderson Cancer Center (CVC)
12:00 p.m. – 1:30 p.m. Lunch (On Your Own)
1:30 p.m.  –  5:00 p.m. Collaborative Group Meetings (closed session)
5:00 p.m. Adjourn for the Day
5:30 p.m. - 7:00 p.m. Reference Set Working Group Meeting (dinner)